Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;148(2):246-53.
doi: 10.1016/j.clim.2013.05.003. Epub 2013 May 15.

The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer

Affiliations
Review

The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer

Lequn Li et al. Clin Immunol. 2013 Aug.

Abstract

The intestinal epithelium and underlying lamina propria contain T cells that play important roles in maintaining colonic homeostasis. These T cells mediate substantial and specific regulation to ensure that pathogenic microorganisms are eliminated while commensal bacteria are tolerated. There is considerable evidence supporting the notion that the altered ratio between Foxp3(+)CD4(+) T regulatory cells and T effector cells in the colonic microenvironment might contribute to the initiation and progression of inflammation and eventually development of colon cancer. Recent findings on the heterogeneity and plasticity of T regulatory cells, such as the identification of IL-17(+)Foxp3(+)CD4(+) and the RORγt(+)Foxp3(+)CD4(+) subsets, in patients with colorectal inflammation and cancer have provided a new twist in our understanding of the pathogenesis of colonic diseases. Phenotypic and functional properties of IL-17-producing Foxp3(+)CD4(+) T cells as well as the significant implications of these cells in the initiation and progression of colorectal diseases are discussed in this review.

Keywords: Colon cancer; IL-17; Inflammatory bowel disease; RORγt; T regulatory cells; Th17.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Induction of TReg cell mediated gut immune tolerance
In the steady state, gut immune tolerance is induced and maintained by a variety of mechanisms, which regulate the differentiation and activation of TReg cells. Some commensal bacteria can induce the differentiation of CD4+ T cells into TReg cells in a TLRs dependent manner. Clostridium spp. can induce generation of IL-10 producing TReg cells via epithelial cell-derived TGF-β, whereas Bacteroides fraglilis can induce IL-10 producing TReg cells via polysaccharide A (PSA). CD103+DC can also induce TReg cells through their ability to produce retinoic acid and TGF-β. TReg cells act on macrophage and myeloid cells to inhibit their ability to produce colitogenic cytokines including IL-12p40, Il-6 and IL-23, which are required for the differentiation of CD4+ T cells into Th1 and Th17 cells. Both Th1 and Th17 cells are associated with initiation and progression of IBD and colon cancer. TReg cells suppress inflammatory responses mainly through production of anti-inflammatory cytokines TGF-β and more importantly IL-10.
Figure 2
Figure 2. Opposing effects of Foxp3+TReg and RORγt+Foxp3+TReg cells in the development of IBD and colon cancer
Foxp3+ TReg cells suppress both T-cell mediated anti-tumor immune response and inflammatory response at least in part by secretion of IL-10 and TGF-β in response to TCR-mediated stimulation. Given their ability to suppress inflammatory processes, Foxp3+ TReg cells play an important role in controlling and suppressing the pathogenesis of IBD and subsequently the development of colon cancer. However, in the context of an inflammatory milieu, Foxp3+ TReg cells are able to express RORγt and have the potential to express and secrete IL-17. The resultant RORγt+Foxp3+TReg cells display potent suppressive activity on T-cell mediated immune responses, whereas their antiinflammatory function is compromised. As a consequence, RORγt+Foxp3+ TReg cells are unable to control inflammation and rather promote instead of suppressing the development of colon cancer.

Similar articles

Cited by

References

    1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–787. - PubMed
    1. Bienenstock J, McDermott M, Befus D, O'Neill M. A common mucosal immunologic system involving the bronchus, breast and bowel. Adv Exp Med Biol. 1978;107:53–59. - PubMed
    1. Jorde R, Burhol PG. Diurnal profiles of gastrointestinal regulatory peptides. Scand J Gastroenterol. 1985;20:1–4. - PubMed
    1. Smart CJ, Trejdosiewicz LK, Badrel-Din S, Heatley RV. T lymphocytes of the human colonic mucosa: functional and phenotypic analysis. Clin Exp Immunol. 1988;73:63–69. - PMC - PubMed
    1. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol. 1995;102:448–455. - PMC - PubMed

Publication types

MeSH terms